This is the sixth prospective vaccine for which the EUROPEAN executive has reached or is an early acquisition agreement.
The proposed contract with the German company BioNTech and the US company Pfizer would lead to an initial acquisition of two hundred million doses, with the option to acquire another $ 100 million, the Commission said after the conclusion of exploratory talks.
All EU members would have the opportunity to buy the vaccine and could simply donate to the poorest countries or redirect them to other European countries.
The EU would be produced through BioNTech’s sites in Germany and Pfizer’s production facilities in Belgium, and deliveries would begin until the end of the year, corporations said in a statement.
They added that they were on track to request a regulatory review of their potential vaccine in October and, subject to approval, planned to supply up to 100 million international doses through the end of 2020 and about 1. 3 billion doses through the end of 2021.
The proposed agreement with the European Commission would be the initial dose order for Pfizer and BioNTech to date, they said.
Corporations are developing a new messenger RNA vaccine (mRNA), which allows the human framework to create viral proteins, prompting the immune formula to produce a defensive response.
The Commission reached an initial agreement last month with AstraZeneca for at least three hundred million doses of its potential vaccine, reflecting measures taken across the United States and other rich states to protect a pool of effective COVID-19 vaccines.
Has concluded exploratory discussions with Sanofi-GSK, Johnson
This story was published from a firm thread without converting the text.
Click here to read that Mint ePapermint is now on Telegram. Join the mint channel in your telegram and updated
Log in to our to save your favorites. It’ll only take a moment.
Your query has expired, reconnect.
You are now subscribed to our newsletters. If you can’t find any of our emails, check your spam folder.